Loss of power and clear description of treatment differences are key issues in designing and analyzing a clinical trial where non-proportional hazard is a possibility. A log-rank test may be very inefficient and interpretation of the hazard ratio estimated using Cox regression is potentially problematic. In this case, the current ICH E9 (R1) addendum would suggest designing a trial with a clinically relevant estimand, e.g., expected life gain. This approach considers appropriate analysis methods for supporting the chosen estimand. However, such an approach is case specific and may suffer lack of power for important choices of the underlying alternate hypothesis distribution. On the other hand, there may be a desire to have robust power under different deviations from proportional hazards. Also, we would contend that no single number adequately describes treatment effect under non-proportional hazards scenarios. The crosspharma working group has proposed a combination test to provide robust power under a variety of alternative hypotheses. These can be specified for primary analysis at the design stage and methods appropriately accounting for combination test correlations are efficient for a variety of scenarios. We have provided design and analysis considerations based on a combination test under different non-proportional hazard types and present a straw man proposal for practitioners.
Introduction
A time to event endpoint is the primary outcome of interest in many clinical trials. Each subject will either experience an event (e.g., disease progression or death) or is censored. Commonly used statistical methods for comparing two survival curves in a randomized trial are the Kaplan-Meier survival plot [1] , log-rank test [2] , and Cox regression [3] . The performance of the log-rank test and Cox regression heavily depend on the proportional hazards (PH) assumption. In reality, the PH assumption is often not met. For example, recent immuno-oncology therapies pose unique challenges to the trial design where a delayed separation of the Kaplan-Meier curves have often been observed, potentially resulting in a violation of proportional hazards (PH) assumption ( [4] , [5] , [6] , [7] ).
Since treatment differences under non-proportional hazard (NPH) constitute a broad class of alternative hypotheses, finding one test and estimate of treatment benefit that are consistently meaningful and provide good statistical power in multiple situations is challenging. Well known NPH types observed in clinical trials are delayed effect, crossing survival, and diminishing effect over time. A more complex situation involves more than one NPH type (e.g. Delayed effect with converging tails). While there may be speculation about the nature of treatment effect at the time of study design, we have found it can often be wrong. This adds to the challenge of designing a trial that will be well-powered and adequately describe the treatment effect over time. Therefore, a suitable design and analysis method for time to event data with potential NPH needs to be flexible enough to incorporate this uncertainty and provide robust inference. In addition, a single treatment effect summary is not adequate to capture the time dependent nature of the benefit. We need measures beyond a simple hazard ratio or restricted mean survival time (RMST) to quantify and communicate the treatment effect.
The goal of this paper is to guide practitioners about strengths and limitations of the available methods of design and analysis of clinical trial with potential NPH. We evaluate them as a candidate for primary analysis in the confirmatory studies. These are meant as straw man proposals for initiating a general discussion with different stakeholders. While considerable thought and background investigation has gone into this proposal by a cross-pharma working group, it is not endorsed by regulatory authorities. Project specific customization is necessary to fulfill the needs in a particular situation.
The rest of the paper is structured as follows. We start with a brief overview of the statistical methods available in the literature and their merit as the primary analysis in confirmatory trials. This is followed by some recommendations for analysis and design approaches when NPH is plausible. Both sections are complemented with illustrative examples. Discussion and concluding remarks are in the last section.
Overview of Available Methods
We begin with a brief review of the available methodologies. Our goal is to provide readers an overview of the strengths and limitations of the available traditional and novel approaches of hypothesis testing and estimation of treatment effect when NPH is present. For this review, we have focused on the methods generally used in drug development. The available methods can be broadly categorized as rank-based, Kaplan-Meier based, time dependent Cox regression (CoxTD) and combination tests.
We start with the rank-based tests. The log-rank (LR) test is the most popular rank-based test for comparing two survival curves. Being nonparametric in nature, the LR test is statistically valid when the PH assumption is not met, but it has poor power in certain situations [4] . The dual or complementary estimand for treatment effect corresponding to the LR test is hazard ratio (HR) generated by the Cox regression proportional hazards model. When the PH assumption is violated, the HR has a limited interpretation. Moreover, it depends on the overall follow-up of patients.
Under NPH, it is not clear what estimand the LR test and HR are associated with. However, the LR test controls type I error well and the HR is familiar to statisticians and non-statisticians as a measure of treatment effect. A good alternative rank-based test is Weighted log-rank (WLR) test when PH assumption is violated. A general class of WLR test was introduced by FlemingHarrington (FH) (G ρ,γ ) [8] with the weight function (Ŝ(t)) ρ (1 −Ŝ(t)) γ (ρ ≥ 0, γ ≥ 0) whereŜ(t) is the estimated survival function immediately prior to time t. Various LR statistics can be obtained by different selections of ρ and γ, that cover large number of NPH scenarios. For example, (ρ, γ)= (1,0) (G 1,0 or Prentice-Wilcoxon test) assigns higher weight to early survival differences. On the contrary, the G 0,0 , G 0,1 and G 1,1 emphasize PH (LR test), late and mid differences respectively.
Other weight functions can also be considered based on the presumed likely treatment effect over time. The dual estimate of treatment effect quantifier for the WLR test is the weighted hazard ratio (WHR) [8, 9] . This is a weighted average treatment effect where the weights are same as the associated WLR test. For instance, the weighted HR corresponding to G 0,1 would down-weight the early treatment effect and be more reflective of the hazard ratio in the later part of the curve. It measures the average treatment effect which does not have a straightforward clinical interpretation.
The choice of ρ and γ requires knowledge of the shape of survival curves and plays an important role to the performance of WLR test and WHR. Mis-specification of the weight function may result in loss of power for WLR test and not meaningful to the WHR estimate. Due to the uncertain nature of NPH at the beginning of the trial, specification of ρ and γ is difficult. Other alternative approaches are piecewise LR test [10, 11] and the piecewise HR. Here, the interval specific LR test statistic is calculated using information within each interval. Finally, an overall test statistic is derived by using a linear combination interval specific ones. The piecewise HR's are estimated by the Cox or parametric models (e.g. exponential). The proposed optimal test [10, 11] may be controversial in many therapeutic areas (e.g., Oncology) as it totally ignores the early events when there is a delay in treatment effect. However, such approaches are well accepted for vaccine trials. Both piecewise LR and piecewise HR heavily depend on the specification of intervals. The piecewise HR captures the time dependent treatment effect well and appeals to the practitioners as a treatment effect quantifier.
The next class of tests is based on the Kaplan-Meier(KM) estimate of the survival function.
Commonly used KM based comparison methods include difference in estimated median, difference in survival or milestone rates, weighted Kaplan-Meier test (WKM), restricted mean survival time (RMST), and restricted mean time lost (RMTL). RMTL is defined as t-RMST which is the area above the survival curve up to time t. Though difference in median is popularly used as a measure of absolute treatment effect under PH scenario, it has a limited interpretation when treatment effect is not constant. A more appealing and intuitive measure is the difference in estimated survival at single or multiple fixed time points [12] . If the time points are appropriately chosen a priori, milestone survival analysis provides clinically meaningful treatment effect estimate (e.g. % gain in survival). On other hand WKM ( Pepe and Fleming 1989 [13] ), RMST (Royston and Parmar, 2011 [14] ) and RMTL are based on the area under the estimated KM curve. An alternative summary for treatment effect is ratio of RMTL. When the event rate is low and the event time distribution is exponential, the ratio of RMTL will be close to the HR. WKM is based on the integrated weighted difference between KM estimators up to a pre-specified time points or the length of the study period (τ ) and measures the difference in mean failure times. It is valid under NPH. The weight function depends on the empirical estimate of the probability of censoring.
The treatment effect estimate based on WKM test statistics is not easy to interpret unless the weight is set as one for each time point. This special case of WKM test statistic is known as the difference in RMST which has a good clinical interpretation in certain situations. It measures the mean time without events or expected lifetime for all patients followed up until time τ . In recent years, the RMST has drawn a great interest in the literature. The notable ones include Royston and Parmar, 2011 [14] ; Tian et al, 2014 [15] and Uno et. al 2014 [16] . Performance of WKM, RMST and RMTL depend heavily on the choice of τ and censoring pattern. Also, a similar RMST difference can reflect a crossing survival curves or curves with a small consistent difference -suggesting that no single (scalar) estimand can adequately summarize the treatment differences under non-proportional hazards. Specifically, different patients or physicians will judge the value early and late survival benefit differently. Simulation studies have shown that the power gain for the WKM and RMST are minimal in comparison to the LR test when there is a delayed effect [17] .
A natural extension of Cox regression model for NPH setting is including a time varying coefficient for treatment [18] . The adjusted time-dependent Cox PH model (CoxTD) considers the following form for the underlying hazard function h(t):
where h 0 (t), β F , and β T are baseline hazard, fixed and time-dependent treatment effects respectively. One major challenge of this model is the specification of f (t) at the beginning of trial.
Typical choices of f (t) include t, √ t, and log(t). Putter et al 2005 [18] recommended goodness of fit based on scaled Schoenfeld residuals to select appropriate form of f (t). Putter et al 2005 [18] also suggested log(t + 1) as a "reasonable" choice for f (t) to diminish the influence of very early events. The treatment effect is tested using a likelihood ratio test with 2 degrees of freedom AND summarized using a time dependent HR along with 95% CI. An extension is proposed by Campbell Spiessens 2017 [20] shows that CoxTD model with f (t) = log(t + 1) suffers significant power loss when the underlying survival pattern is delayed treatment effect. Moreover, reporting the HR as a continuous function of time for the primary treatment effect summary in a confirmatory trial is problematic for non-statistical communication, regulatory submission for drug application and drug labeling.
In recent years, combination tests have been proposed to handle a broad class of survival distributions as alternative hypothesis [21] , [22] , [23] , [20] . Lee In addition to the four families of tests above, we introduce net benefit or the net chance of a longer event-free as proposed by Buyse et. al. 2010 [27] and Pron et al. 2016 [28] . It is defined as the probability that a random patient in the treatment group is event-free by at least a pre-specified difference as compared to a random patient in the control group minus the probability of the reverse situation. A positive value for net benefit indicates that the treatment is better than 
Choice of Primary Analysis Method for a Confirmatory Trial
Based on the ICH E9 guideline [30] , the primary analysis of a trial needs to be planned prior to enrolling patients. This increases the degree of confidence in the final results and conclusions of the trial. A primary analysis involves both testing and estimation of treatment effect that goes to the label of a drug if approved. With potential NPH, it is difficult to specify a statistical method that can provide consistently high power relative to optimal tests across PH and different NPH scenarios.
At first, we perform a qualitative evaluation of the methods described in Section 1. [17] , [20] . In the next subsection we will introduce a new combination test for confirmatory trials which is an improvement over the available tests and provides robust power under various NPH scenarios. If NPH is not expected, we recommend the use of traditional LR test and HR for the primary analysis.
Robust MaxCombo Test
We propose a new combination test as an alternative choice for primary analysis of a confirmatory trial when NPH is a possibility. An extensive simulation study under the null hypothesis and different type of treatment effect scenarios is performed by the cross-pharma working group (Lin et. al. 2018 [17] ). The simulation study also considers varied enrollment patterns, number of events, and total study duration. It
shows that the type I error is well protected below 2.5% under the null hypothesis (no treatment effect). The simulation study also demonstrates robust power of the MaxCombo test under different alternatives. It shows a clear benefit over LR, WKM and RMST in terms of power when the underlying model is delayed effect and crossing survival. The proposed MaxCombo has also showed benefit over the Lee 2007 [21] combination test when the underlying hazard is delayed effect with converging tails [17] . Also Lee's proposal [21] is computationally intensive as it does not use the asymptotic distribution of WLR tests. Moreover, the power loss of the MaxCombo test is minimal (3-4%) as compared to the LR test when underlying treatment effect is PH. We have also performed a simulation study under the strong null scenario as referred by Magirr and Burman 2018 [32] .
The strong null scenario refers to a situation when the survival distribution of treatment group is uniformly inferior to the control group (i.e., S C (t) ≥ S T (t) for all t). Additional simulations
show that the false positive rate is well protected (1.6%) by the MaxCombo test for the scenario mentioned in that paper [32] under realistic enrollment pattern. In summary, the MaxCombo test fulfills the necessary regulatory standards and suitable to be used in a confirmatory trial.
Specification of the Primary Analysis
The primary analysis involves both hypothesis testing and estimation of treatment effect. Under NPH, a single summary statistic measure (e.g. HR or RMST) fails to capture the time dependent treatment effect and is heavily dependent on the follow-up duration. Therefore, multiple treatment effect summaries are critical to summarize and understand the overall risk-benefit profile. Also, it is generally critical that sufficient follow-up is available to characterize both short-and long-term effects. We propose a three step approach for primary analysis using the MaxCombo test when there is a chance of observing NPH. The main goals of the proposed approach are the use of a robust test and provide appropriate treatment effect summaries. In spite of the early specification, the proposed approach reports the best treatment effect summaries in adaptive manner based on the data. Similar approaches based on the LR test and CoxTD were discussed by Royston and
Parmer 2011 [14] and Campbell and Dean 2013 [19] . However, these approaches are less efficient due to a test with low power for important scenarios. It is important to note that this approach is a shift from the traditional paradigm where a dual estimator corresponding to a primary testing procedure is always reported as the primary treatment effect quantifier. For example, the HR from the Cox regression model is always presented as the dual treatment effect quantifier for the LR test
. Similar to all other tests, a statistically significant result also needs to be judged with clinically relevance before regulatory approval in an indication.
•
Step 1 (Test of null hypothesis): The first step involves hypothesis testing part of the primary analysis. Treatment effect should be tested with the MaxCombo test and conclusion regarding the null hypothesis is drawn accordingly. If the MaxCombo test is not significant, one concludes that the benefit of experimental treatment has not been demonstrated.
Step 2 (Assessment of PH): Regardless of the step 1, the PH assumption of the underlying treatment effect needs to be assessed using the Grambsch-Therneau test or G-T test [33] based on the scaled Schoenfeld residuals from a Cox model and other visual diagnostics (KM plot, hazard plot, log-log survival plot).
• Step 3 (Treatment effect summary): The treatment effect quantifiers will depend on the outcome of Step 2 Similar to the p-value, the 95% CI corresponding to the estimated WHR using the best weight from MaxCombo test needs to be adjusted due to the positive correlation between four WLR test statistics. We propose a simultaneous confidence interval procedure by using asymptotic multivariate normal joint distribution of WHR. This calculation is efficiently done by using the efficient integration routine in R and SAS [31] . Further details about the simultaneous confidence interval calculation are provided in Appendix B.
Finally, we recommend to report Kaplan-Meier plot, the milestone survival rates at additional time points, the piecewise HR and the net benefit as supportive measures. These measures are useful to understand the time dependent treatment profile and communicate to non-statisticians easily. Alternatively, one can use CoxTD and provide the time dependent HR along with 95 % CI [18] .
Examples
We For KM based methods, we have minimum of the largest observed time in each of the two groups as a choice of τ . For statistical significance, the p-value from each test is compared at one-sided 2.5% level of significance. In addition, we have calculated the milestone survival rates at additional time points (at 3, 12, 18 and 24 months) and piecewise HR (intervals: 0-3 months, 3-6 months, 6-12 months and > 12 months) to understand the treatment effect over time. Table 2 summarizes the analysis of OS for IM211, KEYNOTE-040, and PA3. As data set for two examples are reconstructed from published KM plots, we do not have the relevant stratification factors used for publication. Therefore, all the analyses in this section are unstratified.
[ Table 2 about here.]
For the crossing survival scenario in IM211, 
Sample Size Calculation
Under PH assumption, the number of events determines the power of a design. But if the PH assumption is violated, enrollment rate, number of events, trial duration and total follow-up time play important roles in the power calculation. The final analysis timing based on the accumulation of events only may produce a design that finishes too early, is under-powered and failed to describe the impact of treatment over time. Therefore, a good design strategy with potential NPH needs to find a balance between the number of events (or sample size) and trial duration. A smaller sample size with fewer events but longer follow-up can provide more power and a better description of late behavior of the survival distribution than a larger sample size trial with short follow-up time.
Unlike the LR test, a closed form expression for the sample size calculation and trial duration is not available for the MaxCombo test. Therefore, we propose a two-step approach for sample size calculation using an iterative procedure when the MaxCombo test is proposed for the primary analysis. If the operating characteristics are not adequate, the previous steps need to be repeated. Both the number of events and the minimum follow-up time need to be adjusted. This procedure continues until an acceptable power and type I error control are achieved. 
Interim Analysis
Planning interim analysis requires a cautious approach when NPH is a possibility. Especially, for later emerging treatment effect scenarios (e.g., delayed effect or crossing survival) one needs to reconsider the traditional implementation of interim analyses. An early interim analysis will have smaller probability of stopping for efficacy and higher probability of crossing any futility bound under a delayed effect or crossing hazard scenario. On the other hand if an interim analysis is too late, it may not be useful. While planning for interim analysis with potential NPH, it is important to find a balance between the risks of stopping too soon before late benefit emerges and the appropriately monitoring of the trial for futility. Therefore unlike PH scenario, the timing of the interim analysis needs to consider both number of events and total follow-up. Incorporating interim analysis for stopping in a design requires important statistical and operational considerations apart from the boundary calculation. This includes timing of interim analysis, probability of stopping, impact on the power and overall benefit-risk etc. These aspects are out of scope for this paper and will be published in the future publications. For timing of the efficacy interim, we recommend complete enrollment, accrual of at least 65-70% of the planned events, and at least 6 months follow-up after last patient enrolled. This will help to reduce the probability of early stopping for false positive results. An early futility analysis is problematic when treatment effect is emerging late. Therefore, we recommend statisticians not to perform futility analysis before 45-50% of planned events are accrued. The recommendation is to stop the trial if and only if the treatment seems harmful (e.g. HR > 1.5).
Example
In this subsection we show an example of sample size calculation in a protocol for two arms (treatment vs control) randomized trial with a time to event endpoint. As mentioned above, when NPH is a possibility both trial duration and number of events are important components of the sample size section of the protocol. Furthermore, we assume that based on the mechanism of treatment and evidence from early stage, there is a possibility for delayed effect. However, considerable uncertainty is associated with the occurrence of NPH and the lag time until treatment benefit emerges.
This is a common phenomenon for immuno-oncology.
We will assume 15 months of constant enrollment, a constant dropout rate of 0.001 per month, control group observations follow an exponential survival distribution with a median of 8 months.
After careful elicitation of all available evidence, we assume a possible delayed treatment effect scenario (alternative hypothesis): no treatment effect for 6 months (HR=1), followed by a large treatment effect (HR= 0.56) thereafter. As this is a confirmatory trial for potential regulatory submission, strict control of 2.5% type I error is required, and those investing in the study wish to ensure 90% power under this NPH scenario. Below are the two steps for sample size calculation:
1. The first step is specification of the minimum follow up time for each patient or trial duration.
We consider total trial duration of 18, 24, 32 and 40 months to compare required sample size for each component of the proposed MaxCombo test (Table 3 ). All sample sizes are calculated using the Hasegawa 2014 [41] .
[ Table 3 about here.]
We note two things in the Table 3 . First, the G 0,1 always results in the smallest sample size and event count requirement among the four WLR tests. Second, we select a study duration of 32 months (15 months enrollment + 17 months follow-up after last patient enrolled) given the steep increase in sample size for smaller trial duration and allowing more than twice the control arm median for minimum follow-up time.
2. We generate the time to event data for 5000 patients (2500 per arm) using exponential distribution with median 8 months (under null). The correlation matrix for four FlemingHarrington WLR test statistics is estimated using the empirical correlation from the large trial. Now using a grid search, the statistical significance boundary for MaxCombo is - 2.286 with a nominal standard normal p-value of 0.011. We confirm type I error and power using simulation under alternate hypotheses of interest.
The initial sample size meets the type I error and power requirement based on 10000 simula- 
Conclusion and Discussion
The development plan for each experimental drug is unique. Current design and analysis approaches of a confirmatory clinical trial with time to event endpoint depend heavily on the proportional hazards assumption which is questionable in many occasions. 
Appendix A: Combination test and Calculation of p-value
The proposed combination test
Using the result from Karrison et al. 2016 [22] , the asymptotic null distribution of four WLR test statistics follows a multivariate distribution with mean 0 and correlation matrix Γ:
With correlation matrix Γ=((η ij )) is of the following form;
Therefore, the one-sided p-value of MaxCombo test is calculated using a multivariate normal calculation given below:
z max is the observed value of MaxCombo test statistic and φ is the pdf of 4-dimensional multivariate distribution. The power calculation of MaxCombo does not have a closed expression.
Therefore, a simulation approach is required for power calculation.
Appendix B: Calculation of Simultaneous Confidence Interval
Let, HR M axCombo is the estimated WHR using the best weight as per MaxCombo and using weighted Cox regression [46] . Therefore, a 100 × (1 − α)% simultaneous confidence interval corresponding for WHR related to MaxCombo can be calculated as HR M axCombo ± C * ×SE(HR M axCombo ).
SE(HR M axCombo
) is the standard error of HR M axCombo and C * is calculated using the asymptotic multivariate normal distribution of WHR [22] .
Appendix C: Calculating interim and final boundaries with one interim analysis
Let t be the fraction of events at interim over planned event count at final analysis. G 0,0 (t), 
Now, the correlation between G 0,0 (t) and G ρ,γ (1); ρ, γ = 0, 1 can be calculated Using independent increment [43] and Karrison 2016 [22] 
Therefore, the correlation between G 0,0 (t) and G ρ,γ (1) corr(G 0,0 (t), G ρ,γ (1)) = V (G Table 4 below:
[ Table 4 about 
